Method for producing the enantiomeric forms of cis 1,3-cyclohexanediol derivatives

Details for Australian Patent Application No. 2004215674 (hide)

Owner Sanofi-Aventis Deutschland GmbH

Inventors Keil, Stefanie; Holla, Wolfgang

Agent Watermark

Pub. Number AU-B-2004215674

PCT Pub. Number WO2004/076390

Priority 103 08 350.2 27.02.03 DE

Filing date 19 February 2004

Wipo publication date 10 September 2004

Acceptance publication date 4 February 2010

International Classifications

C07D 263/32 (2006.01) Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings

C12P 41/00 (2006.01) Processes using enzymes or micro-organisms to separate optical isomers from a racemic mixture

Event Publications

15 September 2005 PCT application entered the National Phase

  PCT publication WO2004/076390 Priority application(s): WO2004/076390

22 December 2005 Assignment before Grant

  Aventis Pharma Deutschland GmbH The application has been assigned to Sanofi-Aventis Deutschland GmbH

4 February 2010 Application Accepted

  Published as AU-B-2004215674

3 June 2010 Standard Patent Sealed

15 September 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004215675-Arylcycloalkyl derivatives with branched side chains as PPAR receptor modulators, method for their production and their use as medicaments

2004215673-3-(2-Phenyl-oxazol-4-yl methoxy) cyclohexylmethoxy acetic acid derivatives and related compounds used as PPAR modulators for treating type 2 diabetes and arteriosclerosis